Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Standard-risk B-cell acute lymphoblastic leukaemia in children, drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether blinatumomab allows chemotherapy to be shortened rather than only added to.
Asparaginase hypersensitivity and silent inactivation, and osteonecrosis in older children.
Delivering a two-year outpatient regimen in low- and middle-income countries, where most children with ALL live.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
3-year DFS 96.
3-year OS 85% vs 68%; HR 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.